Tudriqev pairs a modified herpes virus with nivolumab for melanoma that stopped responding to immunotherapy.

Overview of 5 FDA Priority Review PDUFA decision dates in September 2026, covering novel treatments in rare neurological disorders, oncology, and adolescent cardiology.

The approved treatment Hemlibra maintained low bleeding rates for up to five years in people with hemophilia A, according to ...

Pfizer Inc. (NYSE: PFE) reported financial results for the second quarter of 2026 and raised its full-year 2026 Revenue ...

Study 2 randomized PIK3CA-mutant patients 3:3:1 to gedatolisib/palbociclib/fulvestrant, gedatolisib/fulvestrant, or alpelisib/fulvestrant, using PFS for triplet vs ...

Peptides have become one of the hottest trends in wellness, with promises like faster muscle recovery and healthier aging.

Pluvicto now approved across PSMA+ metastatic prostate cancer, nearly doubling eligible patient population; PSMAddition ...

July 22 (Reuters) - Pfizer (PFE.N), opens new tab said on Wednesday the U.S. Food and Drug Administration had granted priority review to its application seeking expanded approval for its prostate ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: The Pfizer logo is seen in this illustration taken August 3, 2025. REUTERS/Dado Ruvic/Illustration/File Photo July 22 ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental New Drug Application (sNDA) for TALZENNA ® (talazoparib), an oral ...

The Food and Drug Administration has approved a new kind of drug to cut cholesterol. So we've called up NPR health correspondent Rob Stein to learn what it can do. Good morning, Rob. ROB STEIN, BYLINE ...

Watch out, metastatic ER+/HER2- breast cancer. There’s a new targeted agent in town. On Tuesday, the U.S. Food and Drug Administration approved the drug gedatolisib, a multi-targeted kinase inhibitor ...